United States Pharmaceuticals

Elutia Inc (ELUT)

Track

Elutia Inc. experienced significant insider buying activity between November 2025 and January 2026. Multiple executives and insiders, including the CEO and CFO, consistently acquired shares during this period. The most recent transactions occurred on January 30, 2026, involving open market purchases. There have been no reported insider transactions in the last three months.
Ticker: ELUT Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Elutia Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 30 Jan 2026
Value US$747,668.67 | Price 336.47 | Shares 89,721 (-21.8%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-02-02 2026-01-30 B Purchase
3.5
RAKIN KEVIN
Non-Executive Director Large shareholder
89,721 -21.8%
336.47
US$747,669 		89,721 -21.8% 336.47 US$747,669
2026-02-02 2026-01-30 B Purchase
2.4
NEELS GUIDO J
Non-Executive Director
77,882 -22.5%
380.89
US$1,444,649 		77,882 -22.5% 380.89 US$1,444,649
2026-01-29 2026-01-29 B Purchase
2.4
NEELS GUIDO J
Non-Executive Director
70,868 -35.4%
355.10
US$1,130,166 		70,868 -35.4% 355.10 US$1,130,166
2026-01-29 2026-01-28 B Purchase
2.4
NEELS GUIDO J
Non-Executive Director
15,000 +21.8%
1.06
US$15,900 		15,000 +21.8% 1.06 US$15,900
2025-12-23 2025-12-23 PrS Proposed sale
William Matthew Zuga

Former Director

Non-Executive Director
12,613
0.55
US$6,937 		12,613 0.55 US$6,937
2025-12-19 2025-12-17 B Purchase
3.5
RAKIN KEVIN
Non-Executive Director Large shareholder
50,000 +18.4%
0.52
US$25,995 		50,000 +18.4% 0.52 US$25,995
2025-12-18 2025-12-17 B Purchase
3.6
Ferguson Matthew

CHIEF FINANCIAL OFFICER

Officer
60,000 +15.5%
0.53
US$31,800 		60,000 +15.5% 0.53 US$31,800
2025-12-18 2025-12-17 B Purchase
3.3
Colpman David
Non-Executive Director
12,500 +67.2%
0.51
US$6,375 		12,500 +67.2% 0.51 US$6,375
2025-12-18 2025-12-17 B Purchase
3.1
Mills C Randal

PRESIDENT AND CEO

Executive Director
3,000 +0.8%
0.51
US$1,530 		3,000 +0.8% 0.51 US$1,530
2025-12-18 2025-12-17 B Purchase
4.1
Makes Brigid
Non-Executive Director
25,000 +1250.0%
0.52
US$13,000 		25,000 +1250.0% 0.52 US$13,000
2025-12-03 2025-12-02 B Purchase
3.6
Ferguson Matthew

CHIEF FINANCIAL OFFICER

Officer
5,500 +1.5%
0.67
US$3,685 		5,500 +1.5% 0.67 US$3,685
2025-12-03 2025-12-01 PP Planned purchase
3.6
Ferguson Matthew

CHIEF FINANCIAL OFFICER

Officer
4,500 +1.2%
0.65
US$2,925 		4,500 +1.2% 0.65 US$2,925
2025-11-26 2025-11-24 B Purchase
3.1
Mills C Randal

PRESIDENT AND CEO

Executive Director
5,000 +1.4%
0.60
US$3,000 		5,000 +1.4% 0.60 US$3,000
2025-11-19 2025-11-17 B Purchase
3.3
Colpman David
Non-Executive Director
15,500 +500.3%
0.74
US$11,470 		15,500 +500.3% 0.74 US$11,470
2025-11-14 2025-11-13 B Purchase
3.1
Mills C Randal

PRESIDENT AND CEO

Executive Director
3,500 +1.0%
0.76
US$2,660 		3,500 +1.0% 0.76 US$2,660
2025-11-14 2025-11-13 B Purchase
3.1
Mills C Randal

PRESIDENT AND CEO

Executive Director
5,000 +1.4%
0.75
US$3,750 		5,000 +1.4% 0.75 US$3,750
2025-11-14 2025-11-13 PP Planned purchase
3.1
Mills C Randal

PRESIDENT AND CEO

Executive Director
5,000 +1.5%
0.74
US$3,700 		5,000 +1.5% 0.74 US$3,700
2025-03-13 2025-02-03 B Purchase
1.5
HighCape Capital, L.P.
Non-Executive Director Large shareholder
420,000 +4.6%
2.50
US$1,050,000 		420,000 +4.6% 2.50 US$1,050,000
2025-03-13 2025-02-03 B Purchase
1.5
HighCape Capital, L.P.
Non-Executive Director Large shareholder
420,000 +4.6%
2.50
US$1,050,000 		420,000 +4.6% 2.50 US$1,050,000
2023-03-27 2023-03-27 B Purchase
3.7
Birchview Capital, LP
Large shareholder
10,000 +0.6%
1.59
US$15,870 		10,000 +0.6% 1.59 US$15,870
2023-03-27 2023-03-24 B Purchase
3.7
Birchview Capital, LP
Large shareholder
2,000 +0.1%
1.35
US$2,708 		2,000 +0.1% 1.35 US$2,708
2023-03-27 2023-03-24 B Purchase
3.7
Birchview Capital, LP
Large shareholder
18,000 +1.1%
1.35
US$24,370 		18,000 +1.1% 1.35 US$24,370
2023-03-27 2023-03-23 B Purchase
3.7
Birchview Capital, LP
Large shareholder
10,000 +0.6%
1.49
US$14,910 		10,000 +0.6% 1.49 US$14,910
2023-03-27 2023-03-23 B Purchase
3.7
Birchview Capital, LP
Large shareholder
100,000 +6.6%
1.49
US$149,100 		100,000 +6.6% 1.49 US$149,100
2023-03-09 2023-03-09 S Sale
3.3
Englese Thomas

CHIEF COMMERCIAL OFFICER

Officer
289 -1.6%
4.30
US$1,243 		289 -1.6% 4.30 US$1,243
2022-12-16 2022-12-15 B Purchase
3.3
Colpman David
Non-Executive Director
3,098 +inf%
3.90
US$12,082 		3,098 +inf% 3.90 US$12,082
2022-12-12 2022-12-09 B Purchase
4.1
Makes Brigid
Non-Executive Director
2,000 +inf%
3.65
US$7,300 		2,000 +inf% 3.65 US$7,300
2023-02-13 2022-12-08 B Purchase
3.7
Birchview Capital, LP
Large shareholder
4,000 +0.3%
3.79
US$15,141 		4,000 +0.3% 3.79 US$15,141
2023-02-13 2022-12-08 B Purchase
3.7
Birchview Capital, LP
Large shareholder
9,061 +0.6%
3.79
US$34,377 		9,061 +0.6% 3.79 US$34,377
2023-02-13 2022-12-07 B Purchase
3.7
Birchview Capital, LP
Large shareholder
34,000 +2.3%
3.58
US$121,720 		34,000 +2.3% 3.58 US$121,720
2023-02-13 2022-12-07 B Purchase
3.7
Birchview Capital, LP
Large shareholder
10,000 +0.7%
3.58
US$35,800 		10,000 +0.7% 3.58 US$35,800
2022-12-07 2022-12-05 B Purchase
1.5
HighCape Capital, L.P.
Non-Executive Director Large shareholder
735,000 +15.1%
4.75
US$3,491,250 		735,000 +15.1% 4.75 US$3,491,250
2022-12-05 2022-12-05 B Purchase
3.6
Ferguson Matthew

CHIEF FINANCIAL OFFICER

Officer
2,000 +4.6%
3.61
US$7,220 		2,000 +4.6% 3.61 US$7,220
2022-12-05 2022-12-05 B Purchase
3.6
Ferguson Matthew

CHIEF FINANCIAL OFFICER

Officer
20,000 +86.1%
4.75
US$95,000 		20,000 +86.1% 4.75 US$95,000
2022-12-05 2022-12-02 B Purchase
3.6
Ferguson Matthew

CHIEF FINANCIAL OFFICER

Officer
6,000 +34.8%
4.03
US$24,180 		6,000 +34.8% 4.03 US$24,180
2023-02-13 2022-12-01 B Purchase
3.7
Birchview Capital, LP
Large shareholder
40,000 +2.8%
4.75
US$190,000 		40,000 +2.8% 4.75 US$190,000
2023-02-13 2022-05-11 B Purchase
3.7
Birchview Capital, LP
Large shareholder
200 +0.0%
5.96
US$1,192 		200 +0.0% 5.96 US$1,192
2022-03-10 2022-03-10 S Sale
3.3
Englese Thomas

CHIEF COMMERCIAL OFFICER

Officer
276
0.00
US$0 		276 0.00 US$0
2021-12-15 2021-12-14 PP Planned purchase
3.3
Englese Thomas

CHIEF COMMERCIAL OFFICER

Officer
4,580 +901.6%
6.10
US$27,938 		4,580 +901.6% 6.10 US$27,938
2021-12-10 2021-12-08 B Purchase
1.5
HighCape Capital, L.P.
Non-Executive Director Large shareholder
58,962 +185.2%
4.24
US$249,999 		58,962 +185.2% 4.24 US$249,999
2021-12-10 2021-12-08 B Purchase
1.5
HighCape Capital, L.P.
Non-Executive Director Large shareholder
353,773 +7.8%
4.24
US$1,499,998 		353,773 +7.8% 4.24 US$1,499,998
2023-10-05 2021-09-21 B Purchase
HighCape Capital, LLC
Large shareholder
2,837,128
0.00
US$0 		2,837,128 0.00 US$0
2023-10-05 2021-09-21 B Purchase
1.5
HighCape Capital, L.P.
Non-Executive Director Large shareholder
2,837,128
0.00
US$0 		2,837,128 0.00 US$0
2021-05-12 2021-05-11 B Purchase
3.6
Ferguson Matthew

CHIEF FINANCIAL OFFICER

Officer
1,000 +76.9%
11.00
US$11,000 		1,000 +76.9% 11.00 US$11,000
2021-05-12 2021-05-10 B Purchase
3.6
Ferguson Matthew

CHIEF FINANCIAL OFFICER

Officer
1,300 +inf%
11.14
US$14,482 		1,300 +inf% 11.14 US$14,482
2021-05-11 2021-05-07 B Purchase
0.6
LLOYD RONALD K.

PRESIDENT AND CEO

Executive Director
1,367 +6.3%
12.28
US$16,787 		1,367 +6.3% 12.28 US$16,787
2021-05-11 2021-05-07 B Purchase
0.6
LLOYD RONALD K.

PRESIDENT AND CEO

Executive Director
7,198 +49.3%
11.65
US$83,857 		7,198 +49.3% 11.65 US$83,857
2020-10-13 2020-10-13 B Purchase
1.5
HighCape Capital, L.P.
Large shareholder
441,176 +10.8%
17.00
US$7,499,992 		441,176 +10.8% 17.00 US$7,499,992
Explore more

More insider trading research around Elutia Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America